Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013491
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. It has operations in Europe and North America. Vernalis is headquartered in Winnersh, the UK.

Vernalis Plc (VER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Partnerships 12
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Licensing Agreements 19
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Equity Offering 24
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc – Key Competitors 27
Vernalis Plc – Key Employees 28
Vernalis Plc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Sep 12, 2017: Vernalis: Results Announcement for the year ended 30 June 2017 31
Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results 33
Feb 21, 2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016 34
Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016 36
Mar 17, 2016: Vernalis: Unaudited Interim Results Announcement for the six months ended 31 December 2015 38
Mar 17, 2016: Vernalis Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015 43
Corporate Communications 44
Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics 44
Government and Public Interest 45
Dec 01, 2016: Vernalis: AGM Statement 45
Product News 46
12/21/2016: FDA accepts CCP-08 NDA for full review 46
09/06/2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review 47
04/05/2017: Drug makes head-and-neck cancer more sensitive to radiotherapy 48
Product Approvals 49
Aug 07, 2017: FDA Issues a Complete Response Letter on CCP-08 NDA 49
Apr 21, 2017: FDA Issues a Complete Response Letter on CCP-07 NDA 50
Clinical Trials 51
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study 51
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study 52
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Vernalis Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc, Key Competitors 27
Vernalis Plc, Key Employees 28
Vernalis Plc, Subsidiaries 29

★海外企業調査レポート[Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hyundai Motor Company:企業の戦略・SWOT・財務情報
    Hyundai Motor Company - Strategy, SWOT and Corporate Finance Report Summary Hyundai Motor Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • J&P – Avax Sa:企業の戦略・SWOT・財務分析
    J&P - Avax Sa - Strategy, SWOT and Corporate Finance Report Summary J&P - Avax Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Colbun SA (COLBUN)-エネルギー分野:企業M&A・提携分析
    Summary Colbun SA (Colbun) is an electric utility that generates and transmits electricity. It produces electricity from various sources including hydro, diesel, natural gas, coal, wind and biomass. The company has operating and developing interests in various power plants. Colbun also procures elec …
  • Engie Brasil Energia SA (EGIE3):企業の財務・戦略的SWOT分析
    Engie Brasil Energia SA (EGIE3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • NovaMedica LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary NovaMedica LLC (NovaMedica) is a pharmaceutical company that develops drugs for various therapeutic areas. The company offers drugs in the areas of cardiovascular, central nervous system, dermatology, endocrinology, gynecology, infectious disease, gastrointestinal, pediatric, woman’s health, …
  • Cue Energy Resources Ltd (CUE):企業の財務・戦略的SWOT分析
    Summary Cue Energy Resources Ltd (Cue Energy) is an oil and gas exploration and production company that acquires, explores, develops, and produces hydrocarbons, and oil and gas assets. The company holds interests in five exploration permits located in the Carnarvon Basin, offshore Western Australia. …
  • Mahanagar Telephone Nigam Ltd (MTNL):企業の財務・戦略的SWOT分析
    Mahanagar Telephone Nigam Ltd (MTNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Qsc AG (QSC):企業の財務・戦略的SWOT分析
    Summary Qsc AG (Qsc) is a telecommunication company that provides integrated telecommunication and managed services. The company offers services such as cloud and IT outsourcing, Internet of Things services, sap services and consulting, broadband and network services, and colocation services. Its cl …
  • The Netherlands Cancer Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary The Netherlands Cancer Institute (NCI) is a research institute that offers cancer research and treatment services. The institute conducts research in the areas of cell biology, diagnostic oncology, medical oncology, molecular carcinogenesis, biochemistry, biological stress response, gene reg …
  • Trustpower Limited (TPW):企業の財務・戦略的SWOT分析
    Trustpower Limited (TPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Samart Corporation Plc (SAMART):企業の財務・戦略的SWOT分析
    Samart Corporation Plc (SAMART) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • J.F. Shea Co Inc:企業の戦略・SWOT・財務分析
    J.F. Shea Co Inc - Strategy, SWOT and Corporate Finance Report Summary J.F. Shea Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Offshore Marine Management Limited:企業の戦略的SWOT分析
    Offshore Marine Management Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Point Resources AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Point Resources AS (Point Resources) ,is engaged in developing, exploring and production of petroleum products. It explores and produces crude oil, gas and natural gas liquids (NGLs) through Ringhorne, Balder and Jotun fields. Point Resources also offers seismic surveys and drilling services …
  • Pt Mandom Indonesia Tbk:企業の戦略・SWOT・財務情報
    Pt Mandom Indonesia Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Mandom Indonesia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Clementia Pharmaceuticals Inc (CMTA)-製薬・医療分野:企業M&A・提携分析
    Summary Clementia Pharmaceuticals Inc (Clementia) is a biopharmaceutical company that develops and commercializes orphan drugs and therapies. The company’s palovarotene is used for treatment of muscle tissue disorders such as fibrodysplasia ossificans progressive and other diseases. Its palovarotene …
  • ESAB Holdings Ltd:企業の戦略・SWOT・財務情報
    ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Public Broadcasting Service:企業の戦略的SWOT分析
    Public Broadcasting Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Saturn NPO:企業の戦略・SWOT・財務情報
    Saturn NPO - Strategy, SWOT and Corporate Finance Report Summary Saturn NPO - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sujana Universal Industries Ltd. (SUJANAUNI):企業の財務・戦略的SWOT分析
    Sujana Universal Industries Ltd. (SUJANAUNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆